Board of Directors

Innate Immunotherapeutics is governed by a small board which works closely with the company's executive team, together with external consultants and collaborators, to achieve maximum value for the company's stakeholders.

Michael Quinn, BSc BEc MBA (Harvard).

Independent Chairman

As an executive and director Michael has participated in ASX, AIM, NASDAQ and NYSE initial public offerings for life science, electronics and engineering businesses. He has extensive M&A and capital raising experience. After an early career in banking, transport and radiation cross linked plastics in Australia, London and Silicon valley he co-founded Memtec in 1982. Memtec revolutionised filtration in the water and waste water industries and developed large manufacturing and sales operations in Australia, USA, Europe and Asia until it was acquired by US Filter in 1997. In 2013 Michael retired as a director of ResMed Inc (ASX and NYSE: RMD), after 21 years. In 1999 he co-founded Innovation Capital which currently owns substantial holdings in high technology business engaged in alternative energy, medical devices, diagnostics and advanced audio systems.

Christopher C Collins, B.S, M.B.A.


Chris has over 30 years of experience in business management. He founded Nuttall Gear Corporation (New York), which was subsequently acquired by Altra Holdings (Nasdaq: AIMC). Collins has helped acquire, manage and make profitable 17 companies representing various industries. Collins was elected to the US House of Representatives in 2012 and now serves as the Congressman for New York 27 in Western NY. He currently serves on the Energy & Commerce Committee where he is a member of thre subcommittees - Health, Telecommunications and Oversight & Investigations.

Andrew Sneddon, BEcon, CA

Independent Director

Andrew is a former partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the Life Sciences Practise and specialised in fast growth and emerging technology companies working with many companies from start-up to successful global corporations. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges. He has worked across a broad range of industries and is currently a non executive director at ClearView Wealth Limited and the chairman of Elastagen Pty Ltd and TGR BioSciences Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.

Elizabeth Hopkins, B.Sc. (Hons)

Independent Director

Elizabeth (Liz) trained at Oxford University and holds a First Class Honours degree in Pharmacology. She has spent over 20 years successfully commercialising science outcomes and holds several Director positions, including being a Ministerial appointment to the Council of International Accreditation New Zealand. She has previously been Deputy Chair of NZBIO and was CEO at Wool Equities/Keratec, CEO at Encoate (a start-up biotech), and Chief Development Officer at NeuronZ. Liz is currently Director, Research and Innovation at Lincoln University (Christchurch, NZ). Before moving to New Zealand in 2001, she was with Pfizer's European headquarters for 10 years, the last 2 years as a Global Project Manager.

Liz was previously a director of the Company from 1 June 2009 until 19 September 2013 and was reappointed as a Director on 17 October 2013.

Robert Peach Ph.D

Independent Director

Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He is currently on the Board of Directors and Scientific Advisory Board of Avalia Immunotherapies and is a consultant for several other biotechnology companies.

Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand.  

Dr. Peach was appoint as an independent Non-Executive Director on the 2nd of September 2015.

Simon Wilkinson

Managing Director and CEO

Simon has been the Managing Director and Chief Executive Officer of Innate Immunotherapeutics since 2004. He has been a shareholder in the Company since its formation in 2000. Simon has overseen Innate's transition from being a public unlisted New Zealand company trialling a passive immunotherapeutic drug candidate for HIV to being a listed Australian company focused on addressing the significant and unmet need in progressive multiple sclerosis. Prior to his 15 years involvement in biotech, Simon spent 20 years in finance, banking and business management after training as an officer in the Royal New Zealand Navy.